2024-02-15T13:43:07-06:00 2023-06-30 363321958 Desmond & Ahern Ltd 10827 S Western Avenue Chicago IL 60643 990 2022-07-01 366009467 Orthopaedic Research and Education Foundation ORTH 8476989980 9400 W Higgins Road 215 Rosemont IL 60018 Andrew N Pollak MD Treasurer 8476989980 2024-02-15 1 Andrew Pollak MD 999009999 0 Paul Betlinski P01960501 7737794720 2024-02-15 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z OREF Thomas P Sculco MD 9400 W Higgins Road 215 Rosemont IL 60018 7315977 0 X www.oref.org X 1955 IL Improving lives by supporting excellence in orthopaedic research. 17 17 14 0 0 0 3690278 3219832 0 0 282163 422121 0 0 3972441 3641953 1365339 2130495 0 0 1937084 2146586 0 0 892260 960907 1297077 4263330 5574158 -290889 -1932205 22322488 22252031 3875690 4921101 18446798 17330930 The Orthopaedic Research and Education Foundation (OREF) mission is improving lives by supporting excellence in orthopaedic research. OREF's vision is that it will be the leader in supporting orthopaedic research to improve function, eliminate pain and restore mobility. 0 0 4167691 2130495 2130495 Grant program: The purpose of OREF is to support research into the causes and treatment of musculoskeletal diseases and injuries. OREF's niche is supporting surgeon-researchers and PHD-researchers in basic science/translation, clinical, and health services research. OREF's education program offers new orthopaedic medical researchers the opportunity to develop their research interests and skills. Through educational programming, OREF supports emerging talent to help them successfully pursue research careers. 4167691 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 11 0 1 14 1 0 0 0 0 0 0 0 0 0 0 X 17 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CT DC DE FL GA IL IN KS KY LA MA MD ME MI MS MN MO MT NC ND NE NH NM NY OH OK OR PA RI SC SD TN UT VA WA WI WV WY X X Rhonda Dirr and Lee Grossman 8476989980 9400 W Higgins Road Rosemont IL 60018 Thomas P Sculco MD President 5.00 X X 0 0 0 Joshua J Jacobs MD President Elect 5.00 X X 0 0 0 Richard F Kyle MD Past President 5.00 X X 0 0 0 Andrew N Pollak MD Secretary/Treasurer 5.00 X X 0 0 0 Francis Y Lee MD PhD Chair RGC 5.00 X 0 0 0 Jeffrey S Abrams MD Chair, Innovations & Partnership 5.00 X 0 0 0 Richard F Santore MD Chair-Individual Developme 5.00 X 0 0 0 Annunziato Amendola MD Trustee 5.00 X 0 0 0 Daniel J Berry MD Trustee 5.00 X 0 0 0 David C Templeman MD Trustee 5.00 X 0 0 0 Eric V Dremel Trustee 5.00 X 0 0 0 B Sonny Bal MD JD MBA PhD Trustee 5.00 X 0 0 0 Evalina Burger-Van der Walt MD Trustee 5.00 X 0 0 0 James R Ficke MD Trustee 5.00 X 0 0 0 Jeremie M Axe MD Trustee 5.00 X 0 0 0 John D Kelly IV MD Trustee 5.00 X 0 0 0 Karen L Hackett Trustee 5.00 X 0 0 0 Mary Lloyd Ireland MD Trustee 5.00 X 0 0 0 Michael M Chau MD PhD Trustee 5.00 X 0 0 0 Michael P Bolognesi MD Trustee 5.00 X 0 0 0 Nicholas M Bernthal MD Trustee 5.00 X 0 0 0 Stuart Weinstein MD Trustee 5.00 X 0 0 0 Lee Grossman CEO 40.00 X 324493 0 64060 Deborah Cummins VP of Research and Grants 40.00 X 136086 0 42183 Edward Hoover Senior VP of Development 40.00 X 145009 0 54716 Karen Pubentz Sr. Director of Communicat 40.00 X 138009 0 23897 John Johnson Campaigns Director 40.00 X 108644 0 11722 Dan Krupp Corporate Relations/Innova 40.00 X 147484 0 13111 999725 0 209689 6 0 1 0 0 3219832 3219832 324472 324472 3771673 3674024 97649 97649 97649 3641953 0 0 422121 2130495 2130495 361644 229282 52664 79698 1351077 846760 201366 302951 80891 64072 5770 11049 238879 122717 48290 67872 114095 85315 10515 18265 86527 43789 21074 21664 7199 3643 1753 1803 22200 11235 5407 5558 32868 16368 8403 8097 192338 103822 10380 78136 72071 34106 23836 14129 161604 101494 23986 36124 181303 38212 36146 106945 30744 17322 2261 11161 361469 232413 12040 117016 11432 7180 1696 2556 87221 74684 5003 7534 Bad debt 40000 40000 Dues and subscriptions 7614 4782 1130 1702 Miscellaneous 2487 2487 5574158 4167691 514207 892260 231 232 3764516 2510564 1075865 1487666 91304 54606 181754 167611 25575 14143 12757300 13343812 4607697 4841008 22322488 22252031 194009 514904 3062602 3560624 619079 845573 3875690 4921101 X -239896 -1667970 18686694 18998900 18446798 17330930 22322488 22252031 X -1932205 825239 -8902 X X 0 1 X 1 0 X 3198011 3932349 2959720 3690278 3219832 17000190 3198011 3932349 2959720 3690278 3219832 17000190 1607722 15392468 441988 467531 389234 544505 324472 2167730 19167920 0.80300 0.73690 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 X 10561394 44291 1160278 510734 11255229 13241439 6579 -2143996 542628 10561394 10199908 7026 3592759 558254 13241439 7961755 13785 -82175 19900 7873465 8311807 35531 733712 1119295 7961755 0 0 50447 45274 5173 67282 58311 8971 64025 64026 -1 14143 Charitable Remainder Trust Receivable 2755405 Cash Surrender Value of Life Insurance 1853274 Other receivables 12584 Right Of Use - Lease Assets 219745 4841008 Due to Orthopaedic Partners 621756 Lease Liability ST 156277 Lease Liability LT 67540 845573 X 4474429 825239 7763 833002 3641427 526 526 3641953 5590297 16665 16665 5573632 526 526 5574158 Part IV, Line 2b: On behalf of other orthopaedic organizations, the Foundation accepts contributions for which it performs recordkeeping and provides grants requested by those organizations. Part X, Line 2: FIN 48 Note from Audited Financial Statements: The Foundation, an Illinois nonprofit corporation, is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code and applicable state law, except for taxes pertaining to unrelated business income, if any. The Foundation's annual information and income tax returns filed with the federal and state governments are subject to examination generally for three years after they are filed. The Foundation has adopted the requirements for accounting for uncertain tax positions and management has determined that the Foundation was not required to record a liability related to uncertain tax positions as of June 30, 2022. Part XI, Line 2d - Other Adjustments: Change in cash surrender value of life insurance policies -6,447. Change in charitable remainder trust receivable 14,210. Part XII, Line 2d - Other Adjustments: Orthopaedic partner endowment distribution 16,665. 1 Virginia Commonwealth University Office of Research Sponsored Programs 800 East Leigh Street BOX Richmond VA 232980568 546001758 10000 0 Head-to-head Comparison of Appropriateness Criteria for Knee Arthroplasty University of Southern California (USC) Department of Contracts and Grants 3720 S Flower Street 3rd Floor Los Angeles CA 90089 951642394 19601 0 scRNA-seq of Corticosteroid-Induced Osteonecrosis of the Femoral Head Indiana University 509 E 3rd Street Bloomington IN 474013654 356001673 19968 0 A Novel Antibiotic to Reduce Fracture Related Infection in a Murine Model Columbia University Medical Center Sponsored Projects Administration Columbia University 630 West 168th New York NY 10032 135598093 20000 0 The Role of Tendinopathy and Tissue Crosstalk in Osteoarthritis Progression The Hospital for Special Surgery 535 East 70th Street New York NY 10021 131624135 20000 0 Inhibition of Gremlin1 for prevention and treatment of aseptic loosening Washington University in StLouis Campus Box 1054 One Brookings Drive St Louis MO 631304862 430653611 20000 0 Identification & Imaging of Skeletal Muscle Response to Graded Nerve Crush Yale University PO Box 208327 New Haven CT 065208327 060646973 20000 0 Personal Surgical Planning to Avoid THA dislocation: concept of safe zone Steadman Philippon Research Institute 181 W Meadow Dr Suite 1000 Vail CO 81657 880245022 20000 0 2023 - Clinical Research Award - Hip Chondrolabral Dysfunction: the Road for Excision to Repair, Replacement, and Regeneration University of Pittsburgh Office of Sponsored Programs 300 Murdoch Building 3420 Forbes Avenue Pittsburgh PA 15260 250965591 25000 0 Musculoskeletal Oncology Virtual Evaluation Study (MOVES) Washington University in StLouis Campus Box 1054 One Brookings Drive St Louis MO 631304862 430653611 40000 0 Pro-inflammatory macrophage phenotype in synovium during hip OA progression University of Southern California - Keck School of Medicine Department of Contracts and Grants University of Southern California 3 Los Angeles CA 900890701 951642394 49985 0 Efficacy of Dextromethorphan for Pain Management in Total Knee Arthroplasty University of Maryland Baltimore 620 W Lexington Street 4th Floor Baltimore MD 21201-1508 Baltimore MD 21201 526002033 50000 0 The Role of CCN2 in Tendon Healing The Research Foundation for The SUNY on behalf of University at Buffalo The UB Commons 520 Lee Entrance Suite 211 Sponsored Projects Servic Amherst NY 14228 141368361 50000 0 Optimizing Antibiotic-Cement Efficacy in Peri Prosthetic Shoulder Infection The Regents of the University of California Los Angeles University of California Los Angeles Office of Contract and Gran Los Angeles CA 900951406 956006143 50000 0 Functional Impact of Intra-articular ALK1-Fc Therapy in Osteoarthritis The University of Iowa Office of the Vice President for Research Division of Sponsored Prog Iowa City IA 52242 426004813 50000 0 Regional Nerve Blocks to Improve Recovery in Elderly Spinal Fusion Patients The Curators of the University of Missouri Office of Sponsored Programs Administration 601 Turner Avenue Tu Columbia MO 65211 436003859 100000 0 Characterization of Graft Types for Acetabular Labrum Reconstruction The Hospital for Special Surgery 535 East 70th Street New York NY 10021 131624135 150000 0 Modulating pro-fibrotic signaling after ligamentous knee injury Dartmouth-Hitchcock Clinic One Medical Center Drive Lebanon NH 03756 222519596 150000 0 Flurorescence-based identification of necrotizing soft-tissue infection Boston Children's Hospital 300 Longwood Avenue Boston MA 02115 042774441 299745 0 CT Rigidity Analysis for the Assessment of Regenerate Bone Strength Washington University in StLouis Campus Box 1054 One Brookings Drive St Louis MO 631304862 430653611 398996 0 Optimizing Outcomes of Hip Surgery in Borderline Acetabular Dysplasia The Hospital for Special Surgery 535 East 70th Street New York NY 10021 131624135 400000 0 JUPITER 4.0: Risk factors for failure of isolated MPFL reconstruction Part I, Line 2: The Research Grants Committee is responsible for allocating research funding to advance research in the specialty of orthopaedics and is empowered to establish criteria for the allocation and distribution of philanthropic funds to advance research in the specialty of orthopaedics, implement and conduct independent peer review process to select research funding recipients, prepare and distribute necessary promotional information and application forms for research grants and awards and to accept and allocate or decline to allocate, at its sole and absolute discretion, grants and awards for research. One-year grant recipients receive 50% of the funds to start, then 40% after a six-month financial report is received. A final scientific and lay report within 60 days after the grant ends along with a final financial report is required. Once OREF has the final reports the remaining 10% of the funds are released. One-time award/educational grant/lectureship grants receive full payment after they are approved. Documentation is in the file for lectureships, educational programs and awards. Two or three-year grants are paid and spread over the term of the grant. 10% is withheld until all of the reports are received. Multi-year grant recipients submit annual scientific reports which are then reviewed by the original peer review committee member. X X 0 0 0 0 0 0 0 0 0 Lee Grossman CEO 324493 0 0 0 0 0 31523 0 32537 0 388553 0 0 0 Edward Hoover Senior VP of Development 145009 0 0 0 0 0 12891 0 41825 0 199725 0 0 0 Deborah Cummins VP of Research and Grants 136086 0 0 0 0 0 12054 0 30129 0 178269 0 0 0 Karen Pubentz Sr. Director of Communicat 138009 0 0 0 0 0 6469 0 17428 0 161906 0 0 0 Dan Krupp Corporate Relations/Innova 147484 0 0 0 0 0 7781 0 5330 0 160595 0 0 0 X 0 0 0 0 0 Form 990, Part VI, Section B, line 11b The Finance Committee reviewed and approved the Form 990. It was provided to the Board of Directors, who had an opportunity to review the return prior to filing. Form 990, Part VI, Section B, line 12c All Trustees annual conflict of interest statements are on file with the OREF CEO. The CEO reviews meeting agendas prior to the meeting and notifies leadership of any issues that need to be addressed before the discussions take place. Any individual who gives notice of a potential conflict is to abstain from participation in discussions related to that item. Form 990, Part VI, Section B, line 15 The Foundation has a formal process to determine the compensation of its CEO. The process includes the following: 1) Review and approval by the Board of Trustees or Compensation Committee; 2) Use of comparable compensation data; 3) Contemporaneous documentation and record keepping. Form 990, Part VI, Section C, line 19 The Foundation made its governing documents, conflict of interest policy, and financial statements available to the public upon request for the period of disclosure set forth in IRC Section 6104(d). Form 990, Part XI, line 9: Orthopaedic partner endowment distribution -16,665. Change in cash surrender value of life insurance policies -6,447. Change in charitable remainder trust receivable 14,210. Form 990, Part XII, line 2c: The process has not changed from the prior year. Charitable Remainder Trusts Charitable trusts IL T 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0